Medtronic Raises Fiscal 2027 Forecasts Amid Heart Device Demand

Medtronic has revised its fiscal 2027 financial forecasts upward, citing a surge in demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth of 7.25% to 7.75%, an increase from the previous 6.75% to 7.25% range. Additionally, Medtronic raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90, while maintaining the upper limit at $6.

Strategic Investments in Heart and Robotics Technology

In a move to bolster its position in the cardiovascular market, Medtronic announced an $80 million investment in Pi-Cardia, a company specializing in heart-valve repair devices. Medtronic also secured an option to acquire Pi-Cardia for $210 million. Furthermore, the company invested $700 million in Cornerstone Robotics, gaining rights to distribute a robotic surgical device in various international markets.

CEO Geoff Martha emphasized the importance of these investments, noting the potential for growth in emerging markets where the penetration of soft tissue robotic surgery remains below 1%. The investments align with Medtronic's strategy to focus on high-growth segments with significant patient pools.

Quarterly Performance and Market Dynamics

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was primarily driven by the company's pulsed field ablation portfolio, which experienced an 88% surge, reflecting the robust demand for treatments addressing irregular heart rhythms.

The company's overall quarterly results surpassed market expectations, with an adjusted per-share profit of $1.45 on revenue of $9.76 billion, compared to analyst estimates of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Financial Outlook and Market Confidence

Medtronic's CFO Thierry Pieton noted that the company received tariff refunds that nearly offset the duties paid during the quarter. However, future refunds have not been factored into the revised outlook. Despite the challenges, Medtronic's leadership remains optimistic, supported by the broad performance across its business units and the increasing contributions from new growth platforms.

Geoff Martha highlighted the company's steady pace of mergers and acquisitions, focusing on areas with high growth potential and large patient bases. This strategic focus aims to secure Medtronic's leadership in the medical technology sector, particularly in cardiovascular and robotic surgery markets.